Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors

Elena Gazzano, Barbara Rolando, Konstantin Chegaev, Iris C. Salaroglio, Joanna Kopecka, Isabella Pedrini, Simona Saponara, Matteo Sorge, Ilaria Buondonno, Barbara Stella, Alessandro Marengo, Massimo Valoti, Mara Brancaccio, Roberta Fruttero, Alberto Gasco, Silvia Arpicco, Chiara Riganti

PII:	S0168-3659(17)31049-0
DOI:	doi:10.1016/j.jconrel.2017.11.042
Reference:	COREL 9072
To appear in:	*Journal of Controlled Release*
Received date:	10 September 2017
Revised date:	24 November 2017
Accepted date:	25 November 2017

Please cite this article as: Elena Gazzano, Barbara Rolando, Konstantin Chegaev, Iris C. Salaroglio, Joanna Kopecka, Isabella Pedrini, Simona Saponara, Matteo Sorge, Ilaria Buondonno, Barbara Stella, Alessandro Marengo, Massimo Valoti, Mara Brancaccio, Roberta Fruttero, Alberto Gasco, Silvia Arpicco, Chiara Riganti , Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Corel(2017), doi:10.1016/j.jconrel.2017.11.042

Folate-targeted liposomal nitrooxy-doxorubicin: an effective tool against P-glycoprotein-positive and folate receptor-positive tumors

Elena Gazzano[a,§], Barbara Rolando[b,§], Konstantin Chegaev[b], Iris C. Salaroglio[a], Joanna Kopecka[a], Isabella Pedrini[b], Simona Saponara[c], Matteo Sorge[d], Ilaria Buondonno[a], Barbara Stella[b], Alessandro Marengo[b], Massimo Valoti[c], Mara Brancaccio[d], Roberta Fruttero[b], Alberto Gasco[b,§], Silvia Arpicco[b,§,*], Chiara Riganti[a,§,*]

[a]Department of Oncology, University of Torino, via Santena 5/bis, 10126, Torino, Italy

[b]Department of Drug Science and Technology, University of Torino, via Pietro Giuria 9, 10125 Torino, Italy

[c]Department of Life Sciences, University of Siena, via Aldo Moro 2, 53100 Siena, Italy

[d]Department of Molecular Biotechnology and Health Sciences, University of Torino, via Nizza 52, 10126, Torino, Italy

[§] Equal contribution

Corresponding authors: Dr. Silvia Arpicco, Department of Drug Science and Technology, University of Torino, via Pietro Giuria 9, 10125 Torino, Italy; phone: +39116706668; fax: +39116706663; email: silvia.arpicco@unito.it;_Dr. Chiara Riganti, Department of Oncology, University of Torino, via Santena 5/bis, 10126 Torino, Italy; phone: +39116705857; fax: +39116705845; email: chiara.riganti@unito.it